11. The use of any one of claims 1-10, wherein the subject has been pre-treated with ranibizumab or bevacizumab.

12. The use of any one of claims 1-11, wherein the injection occurs not more than once in at least 2 years.

13. The use of claim 12, wherein the injection occurs not more than once in at least 5 years.

14. The use of any one of claims 1-11, wherein the injection is a one-time injection.

15. The use of any one of claims 1-14, wherein the pharmaceutical composition is a suspension.

16. The use of claim 15, further comprising agitating the suspension to ensure even distribution prior to the injection.

17. The use of claim 15 or 16, further comprising warming the suspension to room temperature prior to the injection.

18. The use of any one of claims 15-17, wherein the suspension further comprises a surfactant.

19. The use of claim 18, wherein the surfactant is selected from polysorbates, sodium dodecyl sulfate, sodium lauryl sulfate, lauryl dimethyl amine oxide, polyethoxylated alcohols, polyoxyethylene sorbitan, octoxynol, Brij, pluronic, and polyoxyl castor oil.

20. The use of any one of claims 15-19, wherein the suspension further comprises phenol, mannitol, sorbitol, or sodium chloride.

21. The use of any one of claims 1-20, wherein an antibiotic solution or an atropine sulfate ointment is to be administered after the injection.

22. The use of claim 21, wherein the antibiotic solution comprises ciprofloxacin.

23. The use of any one of claims 1-21, wherein the rAAV2 variant comprises a nucleic acid comprising the sequence of SEQ ID NO: 9 and the sequence of SEQ ID NO: 10.